These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 39159595)

  • 1. Letter Re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
    Ozbay MF; Ilhan Y
    Eur J Cancer; 2024 Oct; 210():114254. PubMed ID: 39159595
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
    Hong H; Qu Y
    Eur J Cancer; 2024 Aug; 207():114173. PubMed ID: 38901119
    [No Abstract]   [Full Text] [Related]  

  • 3. High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
    Klümper N; Cox A; Eckstein M; Kuppe C; Ritter M; Brossart P; Luetkens J; Hölzel M; Stein J; Saal J
    Eur J Cancer; 2024 Jun; 204():114089. PubMed ID: 38703618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for genitourinary tumors.
    Nakayama T; Kitano S
    Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas.
    Hahn AW; Agarwal N
    Cancer Treat Res Commun; 2020; 24():100190. PubMed ID: 32679555
    [No Abstract]   [Full Text] [Related]  

  • 7. Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma.
    Aggen DH; Rosenberg JE
    Nat Rev Clin Oncol; 2024 Jul; 21(7):487-488. PubMed ID: 38622410
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma and renal cell carcinoma.
    Song Y; Peng Y; Qin C
    World J Urol; 2023 Aug; 41(8):2301-2302. PubMed ID: 37410104
    [No Abstract]   [Full Text] [Related]  

  • 9. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
    Rassy E; Assi T; Kattan J
    Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
    Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
    J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
    Meza L; Malhotra J; Favorito C; Pal SK
    Future Oncol; 2022 Jan; 18(1):21-33. PubMed ID: 34766841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.
    Oishi N; Berenberg J; Blumenstein BA; Johnson K; Rivkin SE; Bukowski RM; O'Bryan RM; Stephens RL; Quagliana J; Saiers JH
    Cancer Treat Rep; 1987 Dec; 71(12):1307-8. PubMed ID: 3690547
    [No Abstract]   [Full Text] [Related]  

  • 13. Concomitment spread of a renal cell carcinoma beyond the kidney and a transitional cell carcinoma beyond the bladder.
    Straub B; Müller M; Schrader M; Goessl C; Heicappell R; Miller K
    Int Urol Nephrol; 2000; 32(2):249-50. PubMed ID: 11229641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zschäbitz S; Niegisch G
    Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant advances in chemotherapy for both urothelial and renal cancer.
    BJU Int; 2024 Feb; 133(2):122-123. PubMed ID: 38232742
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging immunotherapies for bladder cancer.
    Kim JW; Tomita Y; Trepel J; Apolo AB
    Curr Opin Oncol; 2015 May; 27(3):191-200. PubMed ID: 25811346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal cell carcinoma and transitional cell carcinomas of the pelvis and bladder in a patient affected by chronic renal failure due to abuse of phenacetin.
    Campo B; Zanitzer L; Torelli T; Bacchioni AM; Ferrari C; Ordesi G; Macchi RM
    Tumori; 1986 Apr; 72(2):215-7. PubMed ID: 3705197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic renal cell and squamous cell carcinoma of single kidney with concurrent transitional cell carcinoma of ipsilateral ureter and urinary bladder.
    Charles RS; Wein AJ; Wilczynski S; Tomaszewski JE; Hanno PM
    Urology; 1992 May; 39(5):470-2. PubMed ID: 1580043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Active immunotherapy of urologic malignancies and tumor-mediated immunosuppression].
    Kübler H; Gschwend JE
    Urologe A; 2008 Sep; 47(9):1122-7. PubMed ID: 18704362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.